NCT02107755View on ClinicalTrials.gov

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 5, 2014

Primary Completion Date

August 3, 2020

Study Completion Date

August 16, 2021

Conditions
Liver MetastasesLung MetastasesRecurrent MelanomaStage IV MelanomaTumors Metastatic to Brain
Interventions
BIOLOGICAL

ipilimumab

Given IV

RADIATION

stereotactic radiosurgery

Undergo stereotactic radiosurgery

OTHER

laboratory biomarker analysis

Blood and tissue samples will be collected for research purposes.

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT02107755 - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter